1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Abpro Bio Co., Ltd.
  6. News
  7. Summary
    A195990   KR7195990007

ABPRO BIO CO., LTD.

(A195990)
End-of-day quote Korea Stock Exchange  -  05-26
855.00 KRW   -0.81%
2021Abpro Bio Co., Ltd. announced that it has received KRW 5.999999552 billion in funding
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in funding
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment Arm
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abpro Bio Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Korea Bond Investment Advisory Co., Ltd.

10/22/2020 EDT

Abpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 15 unregistered non-guaranteed private convertible bonds for the gross proceeds of KRW 10,000,000,000 on October 22, 2020. The transaction will include participation from new investor Korea Bond Investment Advisory Co., Ltd..The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of November 26, 2023. The bonds can be 100% converted into 227,860,821 common shares of the company at a fixed conversion price of KRW 832 per share, representing the stake of 5.27% in the company. The conversion period start date is November 26, 2021 and end date is October 26, 2023. The subscription date is October 22, 2020. The payment date is November 26, 2020. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.


© S&P Capital IQ 2020
All news about ABPRO BIO CO., LTD.
2021Abpro Bio Co., Ltd. announced that it has received KRW 5.999999552 billion in funding
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in fund..
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 15 billion in funding from Merit..
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from..
CI
2020Abpro Bio Co., Ltd. announced that it has received KRW 10 billion in funding from Korea..
CI
2020An unknown buyer cancelled the acquisition of 75% stake in UG Asset Co., Ltd. from Abpr..
CI
2020Microtech Co.,Ltd cancelled the acquisition of 80% stake in Vitro Corporation from Abpr..
CI
2020Abpro Bio Co., Ltd. announced that it expects to receive KRW 10 billion in funding from..
CI
2020ABPRO BIO CO., LTD.(KOSDAQ : A195990) added to S&P Global BMI Index
CI
2019An unknown buyer agreed to acquire 75% stake in UG Asset Co., Ltd. from Abpro Bio Co., ..
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 228 B 180 M 180 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 88,8%
Chart ABPRO BIO CO., LTD.
Duration : Period :
Abpro Bio Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABPRO BIO CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Pui Chan Ian Yan Co-Chief Executive Officer & Director
Jin-Sang Yang Co-Chief Executive Officer & Director
Jae-Hong Jeon Independent Director
Gab-Jin Kang Independent Director
Ki-Chul An Independent Director
Sector and Competitors